Andrey Malyantsev joined the pool of advisers to Petr Bely
Promomed 12 April 2021
Andrey Mladentsev left the post of Executive Director of Promomed Group to focus on investment management, while remaining in the pool of strategic development advisers to the Chairman of the Board of Directors Petr Bely.
With his resignation, the company's management structure will not change. The strategic management of the Group is still carried out by its shareholder Petr Bely; Biokhimik plant (member of the Promomed Group) is headed by Executive Director Dmitry Zemskov, PROMOMED DM LLC is headed by General Director Maxim Smagin.
With his resignation, the company's management structure will not change. The strategic management of the Group is still carried out by its shareholder Petr Bely; Biokhimik plant (member of the Promomed Group) is headed by Executive Director Dmitry Zemskov, PROMOMED DM LLC is headed by General Director Maxim Smagin.
Andrey Mladentsev was invited to the position of executive director of Promomed Group in June last year to strengthen the team to launch the production of Areplivir, a new domestic drug to combat coronavirus infection. The drug was successfully launched in early autumn 2020 and is currently one of the most effective and safe medicines against SARS-CoV-2 virus. Up to 2 million packages of Areplivir are produced every month at the Saransk plant of the Biokhimik JSC. The drug is included in the list of medicines recommended by the Ministry of Health for the treatment of COVID-19, and is included in the list of vital and essential medicines.
